Immunotherapy in Cervical Cancer

Purpose of ReviewThis review aims to summarize the current immunotherapy studies and the potential targeted therapies showing promise in the treatment of cervical cancer.Recent FindingsThere are promising ongoing monotherapy and combination therapy trials using different immune checkpoint inhibitors, poly adenosine diphosphate ribose polymerase inhibitors, tumor angiogenesis inhibitors (i.e., bevacizumab), antibody-drug conjugates, therapeutic vaccines, and tumor-infiltrating T lymphocytes (adoptive immunotherapy). Some of these novel modalities are also being evaluated in combination with standard platinum-based chemotherapy regimen. At this time, pembrolizumab is approved for the treatment of relapsed or metastatic programmed death ligand 1 (PD-L1) positive cervical cancer after frontline chemotherapy treatment.SummaryMultiple novel therapeutic modalities are emerging as safe and effective for the treatment of cervical cancer patients. Development and participation in investigative treatments can provide benefit and improve outcomes in cervical cancer.

Automated summary

Various immunotherapy and targeted therapies are showing promise in the treatment of cervical cancer, including immune checkpoint inhibitors, PARP inhibitors, angiogenesis inhibitors, antibody-drug conjugates, therapeutic vaccines, and adoptive immunotherapy. Participation in these investigative treatments can benefit and improve outcomes for patients with cervical cancer.